文献速递头颈外科

美国头颈癌手术的医院加价情况

Hospital Markup in Head and Neck Cancer Surgery in the US.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

这项横断面研究利用全国住院患者样本分析了2001至2011年间150275例头颈癌手术患者的医院加价情况,发现加价比率范围为0.8至8.7,平均为2.8,最高四分位医院平均加价为4.1。多变量分析显示,私立营利性医院、西部地区医院、西班牙裔种族、既往放疗、合并症和并发症与更高加价显著相关。医院市场集中度改变了营利状态与加价之间的关联。

要点

  • 医院加价比率(收费与成本之比)范围为0.8至8.7,平均为2.8。
  • 最高四分位加价医院更常见为大型、私立营利性医院,且较少为高手术量医院或位于竞争性市场。
  • 私立营利性医院与加价显著升高相关(升高47.9%,95%CI 33.3%-64.2%)。

核心结论

  • 头颈癌手术的医院加价存在广泛差异,25%的医院收费相对于成本增加4倍。
  • 手术价格差异主要与医院营利状态相关。
  • 这些数据提示需要提高透明度以解决医院定价差异。

研究设计与样本

  • 横断面研究,使用全国住院患者样本识别2001至2011年间150275例因恶性上呼吸消化道肿瘤接受头颈癌手术的患者。
  • 加价比率(收费与成本之比)作为连续和分类变量建模。
  • 医院市场集中度使用可变半径赫芬达尔-赫希曼指数评估,数据来自2000、2003、2006和2009年医院市场结构文件。
  • 数据分析时间为2019年5月至2019年7月。

主要发现

  • 150275例患者平均年龄61.8岁(标准差12.6),104974例(70.0%)为男性。
  • 医院加价比率范围为0.8至8.7,平均加价比率为2.8(95%CI 2.7-2.9)。
  • 最低加价四分位医院平均加价比率为1.8(95%CI 1.8-1.9),最高加价四分位(极端加价)医院平均加价比率为4.1(95%CI 4.0-4.2)。
  • 极端加价医院更多为大型医院(77.5% vs 66.6%)、私立营利性医院(19.0% vs 1.3%),较少为高手术量医院(21.0% vs 9.4%)或位于竞争性市场(64.4% vs 82.0%)。
  • 术后并发症在极端加价医院更常见(22.7% vs 17.1%)。

关键数值与推荐

  • 多变量分析中,加价显著升高与以下因素相关:私立营利性医院(升高47.9%,95%CI 33.3%-64.2%)、西部地区医院(升高25.5%,95%CI 12.6%-39.8%)、西班牙裔种族(升高9.8%,95%CI 4.4%-15.5%)、既往放疗(升高5.3%,95%CI 1.3%-9.4%)、合并症(升高3.5%,95%CI 1.7%-5.4%)和并发症(升高2.8%,95%CI 0.3%-5.4%)。
  • 医院市场集中度改变了医院营利状态与加价之间的关联,在中等集中和集中(竞争较弱)市场中,营利性医院的加价更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Marked variation in hospital costs and payments is a target for health care reform efforts. Limited data exist to explain variability in prices for head and neck surgical procedures. OBJECTIVE: To characterize variations in hospital price markup for head and neck cancer surgery, and examine associations with market concentration and hospital for-profit status. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study, the Nationwide Inpatient Sample was used to identify 150 275 patients who underwent head and neck cancer surgery for a malignant upper aerodigestive tract neoplasm from 2001 to 2011. The markup ratio (charges to costs) was modeled as a continuous and categorical variable. Hospital market concentration was evaluated using a variable-radius Herfindahl-Hirschman Index from the 2000, 2003, 2006, and 2009 Hospital Market Structure files. Data were analyzed from May 2019 to July 2019. MAIN OUTCOMES AND MEASURES: Multivariable regression was used to evaluate associations between hospital and patient variables and hospital markup. RESULTS: There were 150 275 patients (mean [SD] age, 61.8 [12.6] years; 104 974 [70.0%] male) from 2001 to 2011 for whom hospital market information was available. Hospital markup ratios ranged from 0.8 to 8.7, with a mean markup ratio of 2.8 (95% CI, 2.7-2.9). Hospitals in the lowest markup ratio quartile had a mean markup ratio of 1.8 (95% CI, 1.8-1.9), while hospitals in the top markup ratio quartile (extreme markup) had a mean markup ratio of 4.1 (95% CI, 4.0-4.2). Extreme markup hospitals were more often large (77.5% vs 66.6%), private for-profit hospitals (19.0% vs 1.3%), and were less likely to be high-volume hospitals (21.0% vs 9.4%) or in competitive markets (64.4% vs 82.0%). Postoperative complications occurred more often in extreme markup hospitals (22.7% vs 17.1%). On multivariate analysis, a significantly higher markup was associated with private, for-profit hospitals (47.9%; 95% CI, 33.3%-64.2%), hospitals in the West (25.5%; 95% CI, 12.6%-39.8%), Hispanic race (9.8%; 95% CI, 4.4%-15.5%), prior radiation therapy (5.3%; 95% CI, 1.3%-9.4%), comorbidity (3.5%; 95% CI, 1.7%-5.4%), and complications (2.8%; 95% CI, 0.3%-5.4%). Hospital market concentration modified the association between hospital for-profit status and markup, with higher markups in for-profit hospitals in moderately concentrated and concentrated (less competitive) markets. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, there was wide variation in hospital markup for head and neck cancer surgery, with a 4-fold increase in charges relative to costs in 25% of hospitals. Variations in surgical price were primarily associated with hospital profit status. These data suggest that greater transparency is needed to address disparities in hospital pricing.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Miller JR, Frick KD, Gourin CG, et al. Hospital Markup in Head and Neck Cancer Surgery in the US. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 36301556. doi:10.1001/jamaoto.2022.3340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。